Compare Five9 Inc (FIVN) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five9 Inc vs Tango Therapeutics Inc. — how do they compare? Five9 Inc trades at $33.37 (market cap $2.65B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Tango Therapeutics Inc. is the larger of the two by market cap, and Five9 Inc is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Five9 Inc for 72 Days and Tango Therapeutics Inc. for 0 Days on average.
| FIVN | TNGX | |
|---|---|---|
Market Cap | $2.65B | $3.75B |
Volume | 971,747 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $38.65 | $32.90 |
52-Week Low | $13.61 | $7.50 |
Typical Hold Time | 72 Days | 0 Days |
Enterprise Value | $2.80B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five9 (FIVN) trades at $33.08, down 7.26% today amid recent volatility, though the stock remains near its 52-week high of $39.55. The company shows strong fundamental momentum with three consecutive quarterly earnings beats and accelerating AI revenue growth reaching 78% year-over-year. Technical indicators suggest a bullish trend with moving averages supporting upside potential, while RSI levels remain neutral. Five9 maintains leadership in the contact center-as-a-service market with improving profitability margins.
The outlook remains positive with analyst consensus favoring Buy ratings (61%) and a $34 price target representing 3% upside. Key opportunities include AI revenue expansion and market leadership, while risks involve insider selling activity and competitive pressures in the CCaaS space. The company's transition to profitability and strong subscription growth support continued investor interest.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
